Modulation of γ- and β-Secretases as Early Prevention Against Alzheimer's Disease.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Biological Psychiatry

• Publication date

  2018-02-15

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/j.biopsych.2017.08.001PMID 28918941
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Alzheimer's-Causing Mutations Shift Aβ Length by Destabilizing γ-Secretase-Aβn Interactions.

  2017influential reference
• Inactivation of γ‐secretases leads to accumulation of substrates and non‐Alzheimer neurodegeneration

  2017cited by this paper
• Solanezumab: too late in mild Alzheimer's disease?

  2017cited by this paper
• Decreased plasma β‐amyloid in the Alzheimer's disease APP A673T variant carriers

  2017cited by this paper
• Merck ends trial of potential Alzheimer’s drug verubecestat

  2017cited by this paper
• Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of β-secretase inhibitors

  2016cited by this paper
• The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

  2016cited by this paper
• The Cellular Phase of Alzheimer's Disease.

  2016cited by this paper
• Alternative Selection of β-Site APP-Cleaving Enzyme 1 (BACE1) Cleavage Sites in Amyloid β-Protein Precursor (APP) Harboring Protective and Pathogenic Mutations within the Aβ Sequence*

  2016cited by this paper
• BACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer's Disease.

  2016cited by this paper
• Antibody-Based Drugs and Approaches Against Amyloid-β Species for Alzheimer’s Disease Immunotherapy

  2016cited by this paper
• Why cells need intramembrane proteases – a mechanistic perspective

  2016cited by this paper
• The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients

  2016influential reference
• Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of Aβ42 and Aβ40 peptides by γ-secretase

  2016cited by this paper
• Pharmacological BACE1 and BACE2 inhibition induces hair depigmentation by inhibiting PMEL17 processing in mice

  2016cited by this paper
• Presenilin 1 and Presenilin 2 Target γ-Secretase Complexes to Distinct Cellular Compartments*

  2016cited by this paper
• AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer’s Disease

  2016cited by this paper
• Seizure protein 6 and its homolog seizure 6-like protein are physiological substrates of BACE1 in neurons

  2016cited by this paper
• Generation and deposition of Aβ43 by the virtually inactive presenilin‐1 L435F mutant contradicts the presenilin loss‐of‐function hypothesis of Alzheimer's disease

  2016influential reference
• AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics

  2016cited by this paper
• Restricted Location of PSEN2/γ-Secretase Determines Substrate Specificity and Generates an Intracellular Aβ Pool.

  2016cited by this paper
• Reversible and Species-Specific Depigmentation Effects of AZD3293, a BACE Inhibitor for the Treatment of Alzheimer's Disease, Are Related to BACE2 Inhibition and Confined to Epidermis and Hair.

  2016cited by this paper
• Substrate recruitment of γ‐secretase and mechanism of clinical presenilin mutations revealed by photoaffinity mapping

  2016cited by this paper
• The amyloid hypothesis of Alzheimer's disease at 25 years

  2016cited by this paper
• Familial Alzheimer's Disease Mutations in Presenilin Generate Amyloidogenic Aβ Peptide Seeds.

  2016influential reference
• Design of potent and highly selective inhibitors for human β-secretase 2 (memapsin 1), a target for type 2 diabetes

  2016cited by this paper
• Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibition Impairs Synaptic Plasticity via Seizure Protein 6.

  2016cited by this paper
• An atomic structure of human γ-secretase

  2015cited by this paper
• Understanding intramembrane proteolysis: from protein dynamics to reaction kinetics.

  2015cited by this paper
• Label-free Quantitative Proteomics of Mouse Cerebrospinal Fluid Detects β-Site APP Cleaving Enzyme (BACE1) Protease Substrates In Vivo*

  2015cited by this paper
• APP Metabolism Regulates Tau Proteostasis in Human Cerebral Cortex Neurons

  2015cited by this paper
• Qualitative changes in human γ-secretase underlie familial Alzheimer’s disease

  2015cited by this paper
• The Potent BACE1 Inhibitor LY2886721 Elicits Robust Central Aβ Pharmacodynamic Responses in Mice, Dogs, and Humans

  2015cited by this paper
• The dynamic conformational landscape of γ-secretase

  2015cited by this paper
• Presenilin-1 knockin mice reveal loss-of-function mechanism for familial Alzheimer's disease.

  2015cited by this paper
• Sampling the conformational space of the catalytic subunit of human γ-secretase

  2015cited by this paper
• η-Secretase processing of APP inhibits neuronal activity in the hippocampus

  2015cited by this paper
• Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions.

  2015cited by this paper
• Antagonistic Effects of BACE1 and APH1B-γ-Secretase Control Axonal Guidance by Regulating Growth Cone Collapse

  2015cited by this paper
• The Alzheimer Disease Protective Mutation A2T Modulates Kinetic and Thermodynamic Properties of Amyloid-β (Aβ) Aggregation*

  2014cited by this paper
• Molecular Mechanisms of Alzheimer’s Disease Protection by the A673T Allele of Amyloid Precursor Protein

  2014cited by this paper
• Cell autonomous regulation of hippocampal circuitry via Aph1b-γ-secretase/neuregulin 1 signalling

  2014cited by this paper
• Signature Amyloid beta Profiles Are Produced by Different gamma-Secretase Complexes

  2014cited by this paper
• Combined Treatment with a BACE Inhibitor and Anti-Aβ Antibody Gantenerumab Enhances Amyloid Reduction in APPLondon Mice

  2014cited by this paper
• Alzheimer Presenilin-1 Mutations Dramatically Reduce Trimming of Long Amyloid β-Peptides (Aβ) by γ-Secretase to Increase 42-to-40-Residue Aβ*

  2014cited by this paper
• Structural Interactions between Inhibitor and Substrate Docking Sites Give Insight into Mechanisms of Human PS1 Complexes

  2014cited by this paper
• Signature Amyloid β Profiles Are Produced by Different γ-Secretase Complexes*

  2013cited by this paper
• Bace1 and Neuregulin-1 cooperate to control formation and maintenance of muscle spindles

  2013cited by this paper
• γ-secretase modulators and presenilin 1 mutants act differently on presenilin/γ-secretase function to cleave Aβ42 and Aβ43.

  2013cited by this paper
• Increased in Vivo Amyloid-β42 Production, Exchange, and Loss in Presenilin Mutation Carriers

  2013cited by this paper
• BACE2 processes PMEL to form the melanosome amyloid matrix in pigment cells

  2013cited by this paper
• Dual Cleavage of Neuregulin 1 Type III by BACE1 and ADAM17 Liberates Its EGF-Like Domain and Allows Paracrine Signaling

  2013cited by this paper
• A fast growing spectrum of biological functions of γ-secretase in development and disease.

  2013cited by this paper
• Presenilin-1 adopts pathogenic conformation in normal aging and in sporadic Alzheimer’s disease

  2013cited by this paper
• γ-Secretase Associated with Lipid Rafts

  2013cited by this paper
• The precision of axon targeting of mouse olfactory sensory neurons requires the BACE1 protease

  2012cited by this paper
• β-Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment

  2012cited by this paper
• The mechanism of γ-Secretase dysfunction in familial Alzheimer disease

  2012cited by this paper
• The Neural Cell Adhesion Molecules L1 and CHL1 Are Cleaved by BACE1 Protease in Vivo*

  2012cited by this paper
• Tau as a therapeutic target in neurodegenerative disease.

  2012cited by this paper
• P4‐196: The novel BACE inhibitor MK‐8931 dramatically lowers cerebrospinal fluid Aβ peptides in healthy subjects following single‐ and multiple‐dose administration

  2012cited by this paper
• A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline

  2012cited by this paper
• Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons

  2012cited by this paper
• β-Site Amyloid Precursor Protein (APP)-cleaving Enzyme 1 (BACE1)-deficient Mice Exhibit a Close Homolog of L1 (CHL1) Loss-of-function Phenotype Involving Axon Guidance Defects*♦

  2012cited by this paper
• Presenilin 1 and 2 are expressed differentially in the cerebral cortex of mice during development.

  2012cited by this paper
• Minor contribution of presenilin 2 for γ-secretase activity in mouse embryonic fibroblasts and adult mouse brain.

  2011cited by this paper
• Potent amyloidogenicity and pathogenicity of Aβ43

  2011cited by this paper
• The Alzheimer's β-secretase enzyme BACE1 is required for accurate axon guidance of olfactory sensory neurons and normal glomerulus formation in the olfactory bulb

  2011cited by this paper
• Crystal Structure of the Amyloid-β p3 Fragment Provides a Model for Oligomer Formation in Alzheimer's Disease

  2011cited by this paper
• Bace2 is a β cell-enriched protease that regulates pancreatic β cell function and mass.

  2011cited by this paper
• Regulated intramembrane proteolysis: signaling pathways and biological functions.

  2011cited by this paper
• A Therapeutic Antibody Targeting BACE1 Inhibits Amyloid-β Production in Vivo

  2011cited by this paper
• The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics

  2011cited by this paper
• Inhibition of β-Secretase in Vivo via Antibody Binding to Unique Loops (D and F) of BACE1*

  2011cited by this paper
• 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.

  2010cited by this paper
• Correlating familial Alzheimer's disease gene mutations with clinical phenotype.

  2010cited by this paper
• Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease.

  2010cited by this paper
• Substrate docking to γ-secretase allows access of γ-secretase modulators to an allosteric site

  2010cited by this paper
• γ-Secretase: Successive Tripeptide and Tetrapeptide Release from the Transmembrane Domain of β-Carboxyl Terminal Fragment

  2009cited by this paper
• γ-Secretase Heterogeneity in the Aph1 Subunit: Relevance for Alzheimer’s Disease

  2009cited by this paper
• Mapping the human membrane proteome: a majority of the human membrane proteins can be classified according to function and evolutionary origin

  2009cited by this paper
• Allosteric Modulation of PS1/γ-Secretase Conformation Correlates with Amyloid β42/40 Ratio

  2009cited by this paper
• Deficiency of Aph1B/C-γ-secretase disturbs Nrg1 cleavage and sensorimotor gating that can be reversed with antipsychotic treatment

  2008cited by this paper
• Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice

  2008cited by this paper
• BACE1 gene deletion: impact on behavioral function in a model of Alzheimer's disease.

  2008cited by this paper
• Proteomic Profiling of γ-Secretase Substrates and Mapping of Substrate Requirements

  2008cited by this paper
• The presenilin hypothesis of Alzheimer's disease: Evidence for a loss-of-function pathogenic mechanism

  2007cited by this paper
• Pathological activity of familial Alzheimer's disease-associated mutant presenilin can be executed by six different gamma-secretase complexes.

  2007cited by this paper
• Sez-6 proteins affect dendritic arborization patterns and excitability of cortical pyramidal neurons.

  2007cited by this paper
• The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimer’s Disease

  2007cited by this paper
• Bace1 modulates myelination in the central and peripheral nervous system

  2006cited by this paper
• Control of Peripheral Nerve Myelination by the ß-Secretase BACE1

  2006cited by this paper
• Phenotypic and Biochemical Analyses of BACE1- and BACE2-deficient Mice*

  2005cited by this paper
• Identification of Distinct γ-Secretase Complexes with Different APH-1 Variants*

  2004cited by this paper
• Clinical, pathological, and biochemical spectrum of Alzheimer disease associated with PS-1 mutations.

  2004cited by this paper
• Coordinated and widespread expression of gamma-secretase in vivo: evidence for size and molecular heterogeneity.

  2004cited by this paper
• Identification of distinct gamma-secretase complexes with different APH-1 variants.

  2004cited by this paper
• Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration.

  2004cited by this paper
• BACE (beta-secretase) modulates the processing of APLP2 in vivo.

  2004cited by this paper
• Cleavage of amyloid-beta precursor protein and amyloid-beta precursor-like protein by BACE 1.

  2004cited by this paper

• Neutrophil glycolysis mediates colitis-induced exacerbation of Alzheimer's disease.

  2025cites this paper
• DSS-induced colitis exacerbates Alzheimer's pathology via neutrophil elastase and cathepsin B activation.

  2025cites this paper
• Amyloidogenic and non-amyloidogenic pathways of amyloid precursor protein processing in oligodendrocytes.

  2025cites this paper
• Fibrillar amyloidosis and synaptic vesicle protein expression progress jointly in the cortex of a mouse model with β-amyloid pathology

  2025cites this paper
• Cleavage efficiency of the intramembrane protease γ‐secretase is reduced by the palmitoylation of a substrate's transmembrane domain

  2024cites this paper
• Dual Drug Repurposing: The Example of Saracatinib

  2024cites this paper
• Machine learning-based screening of in-house database to identify BACE-1 inhibitors

  2023cites this paper
• A delay in vesicle endocytosis by a C-terminal fragment of N-cadherin enhances Aβ synaptotoxicity

  2023cites this paper
• Role of trigger receptor 2 expressed on myeloid cells in neuroinflammation－neglected multidimensional regulation of microglia.

  2023cites this paper
• Gamma-secretase modulators: a promising route for the treatment of Alzheimer's disease

  2023cites this paper
• Role of neuroinflammation in neurodegeneration development

  2023cites this paper
• Novel small molecular compound 2JY-OBZ4 alleviates AD pathology in cell models via regulating multiple targets

  2022cites this paper
• PICALM and Alzheimer’s Disease: An Update and Perspectives

  2022cites this paper
• Focus on Alzheimer's disease: the role of fibroblast growth factor 21 and autophagy.

  2022cites this paper
• Role of TREM2 in the Development of Neurodegenerative Diseases After Traumatic Brain Injury

  2022cites this paper
• Synaptic dysfunction in early phases of Alzheimer's Disease.

  2022cites this paper
• Extracellular RNA in Alzheimer’s disease

  2021cites this paper
• Dysregulated expression levels of APH1B in peripheral blood are associated with brain atrophy and amyloid-β deposition in Alzheimer’s disease

  2021cites this paper
• Potential of Ramalin and Its Derivatives for the Treatment of Alzheimer’s Disease

  2021cites this paper
• Looking at Alzheimer’s Disease Pathogenesis from the Nuclear Side

  2021cites this paper
• TREM2: Keeping Pace With Immune Checkpoint Inhibitors in Cancer Immunotherapy

  2021cites this paper
• The Amyloid-β Pathway in Alzheimer’s Disease

  2021cites this paper
• Novel ligands and modulators of triggering receptor expressed on myeloid cells receptor family: 2015-2020 updates

  2021cites this paper
• Dementia prevention, intervention, and care: 2020 report of the Lancet Commission

  2020cites this paper
• Accelerated neuronal and synaptic maturation by BrainPhys medium increases Aβ secretion and alters Aβ peptide ratios from iPSC-derived cortical neurons

  2020cites this paper
• The main targets involved in neuroprotection for the treatment of Alzheimer's Disease and Parkinson Disease.

  2020cites this paper
• The Physiology, Pathology, and Potential Therapeutic Applications of the TREM2 Signaling Pathway.

  2020cites this paper
• New BACE1 Chimeric Peptide Inhibitors Selectively Prevent AβPP-β Cleavage Decreasing Amyloid-β Production and Accumulation in Alzheimer’s Disease Models

  2020cites this paper
• Super-resolution microscopy reveals majorly mono- and dimeric presenilin1/γ-secretase at the cell surface

  2020cites this paper
• Behavioral and neural network abnormalities in human APP transgenic mice resemble those of App knock-in mice and are modulated by familial Alzheimer’s disease mutations but not by inhibition of BACE1

  2020cites this paper
• Dysfunctional proteins in neuropsychiatric disorders: from neurodegeneration to Autism Spectrum Disorders.

  2020cites this paper
• Aβ Plaques.

  2020cites this paper
• Alzheimer’s Disease and Dementia

  2019cites this paper
• Icaritin, an inhibitor of beta-site amyloid cleaving enzyme-1, inhibits secretion of amyloid precursor protein in APP-PS1-HEK293 cells by impeding the amyloidogenic pathway

  2019cites this paper
• EphA4 loss improves social memory performance and alters dendritic spine morphology without changes in amyloid pathology in a mouse model of Alzheimer’s disease

  2019cites this paper
• Prionoid Proteins in the Pathogenesis of Neurodegenerative Diseases

  2019cites this paper
• Natural Compounds with Anti-BACE1 Activity as Promising Therapeutic Drugs for Treating Alzheimerʼs Disease

  2019cites this paper
• Alzheimer Disease: An Update on Pathobiology and Treatment Strategies

  2019cites this paper
• Amyloid β oligomers inhibit growth of human cancer cells

  2019cites this paper
• AAV mediated delivery of a novel anti-BACE1 VHH reduces Abeta in an Alzheimer’s disease mouse model

  2019cites this paper
• Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease

  2019cites this paper
• A42/A40 Ratios of Presenilin 1 Mutations Correlate with Clinical Onset of Alzheimer's Disease

  2019cites this paper
• QSAR Classification Models for Predicting the Activity of Inhibitors of Beta-Secretase (BACE1) Associated with Alzheimer’s Disease

  2019cites this paper
• Developments with multi-target drugs for Alzheimer’s disease: an overview of the current discovery approaches

  2019cites this paper
• Therapeutic potential of cyanobacterial pigment protein phycoerythrin: in silico and in vitro study of BACE1 interaction and in vivo Aβ reduction.

  2019cites this paper
• A Unifying Hypothesis for Alzheimer's Disease: From Plaques to Neurodegeneration.

  2019cites this paper
• Therapeutic Strategies Targeting Amyloid-β in Alzheimer's Disease.

  2019cites this paper
• BACE-1 and γ-Secretase as Therapeutic Targets for Alzheimer’s Disease

  2019cites this paper
• Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment

  2018cites this paper
• Visualization of Alzheimer’s Disease Related α-/β-/γ-Secretase Ternary Complex by Bimolecular Fluorescence Complementation Based Fluorescence Resonance Energy Transfer

  2018cites this paper
• BACE2 distribution in major brain cell types and identification of novel substrates

  2018cites this paper
• Aβ42/Aβ40 Ratios of Presenilin 1 Mutations Correlate with Clinical Onset of Alzheimer’s Disease

  2018cites this paper
• TREM2 — a key player in microglial biology and Alzheimer disease

  2018cites this paper
• Paradoxical effects of mutant ubiquitin on Aβ plaque formation in an Alzheimer mouse model.

  2018cites this paper
• Early Aβ-HBc virus-like particles immunization had better effects on preventing the deficit of learning and memory abilities and reducing cerebral Aβ load in PDAPP mice.

  2018cites this paper
• Emerging Mechanisms in Alzheimer's Disease and Their Therapeutic Implications.

  2018cites this paper
• Consequences of Pharmacological BACE Inhibition on Synaptic Structure and Function.

  2018cites this paper
• Dementia prevention, intervention, and care: 2020 report of the Dementia prevention, intervention, and care: 2020 report of the Lancet Commission Lancet Commission

  year unknowncites this paper